• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)

    3/29/24 8:04:05 AM ET
    $GTH
    Medical Specialities
    Health Care
    Get the next $GTH alert in real time by email
    SC 13D/A 1 sc13da1.htm SCHEDULE 13D, AMENDMENT NO. 1

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
    Genetron Holdings Limited
    (Name of Issuer)
     
    Ordinary shares, par value $0.00002 per share
    (Title of Class of Securities)
     
    37186H209**
    (CUSIP Number)
     
    Mr. Sizhen Wang
    FHP Holdings Limited
    c/o 1-2/F, Building 11, Zone 1, No. 8 Life Science Parkway Changping District,
    Beijing, 102206, People’s Republic of China
    +86 (10) 5090-7500
    (Name, Address and Telephone Number of Person Authorized to
    Receive Notices and Communications)
     
     March 28, 2024
    (Date of Event Which Requires Filing of this Statement)
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
    *  This statement on Schedule 13D constitutes Amendment No. 1 (“Amendment No. 1”) to the Schedule 13D filed jointly by Mr. Sizhen Wang and FHP Holdings Limited with U.S. Securities and Exchange Commission (the “SEC”) on October 20, 2023 (the “Original Filing”), with respect to ordinary shares, par value US$0.00002 per share (“ordinary shares”) and American depositary shares (“ADSs”), of Genetron Holdings Limited, a Cayman Islands company (the “Company”). Except as amended hereby, the Original Filing remains in full force and effect. Capitalized terms used but not defined in this Amendment No. 1 have the meanings ascribed to them in the Original Filing.
    ** There is no CUSIP number assigned to the ordinary shares. CUSIP number 37186H209 has been assigned to the ADSs of the Company, which are quoted on NASDAQ Global Market under the symbol “GTH.” Each ADS represents fifteen (15) ordinary shares.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




    CUSIP No. 37186H209
    13D
    Page 1 of 6 Pages


    1
    NAMES OF REPORTING PERSONS
     
    Sizhen Wang
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)  ⌧
    (b)  ☐
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    OO
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
     
    ☐
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    The People’s Republic of China
    NUMBER OF SHARES
    BENEFICIALLY OWNED
    BY EACH
    REPORTING PERSON
    WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    0
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    0
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
     
    ☐
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    0%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN





    CUSIP No. 37186H209
    13D
    Page 2 of 6 Pages


    1
    NAMES OF REPORTING PERSONS
     
    FHP Holdings Limited
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)  ⌧
    (b)  ☐
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    AF
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
     
    ☐
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    British Virgin Islands
    NUMBER OF SHARES
    BENEFICIALLY OWNED
    BY EACH
    REPORTING PERSON
    WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    0
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    0
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
     
    ☐
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    0%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    CO





    CUSIP No. 37186H209
    13D
    Page 3 of 6 Pages

    Item 4. Purpose of Transaction.

    Item 4 of the Schedule 13D is hereby amended by incorporating the following:
    On February 21, 2024, at 9:00 a.m. (Beijing Time), an extraordinary general meeting of the shareholders of the Company was held at 1/F, Building 11, Zone 1, No. 8 Life Science Parkway, Changping District, Beijing, the People’s Republic of China. At the extraordinary general meeting, the shareholders of the Company authorized and approved the Merger Agreement, the Plan of Merger required to be registered with the Registrar of Companies of the Cayman Islands in connection with the Merger and the consummation of the transactions contemplated thereby, including the Merger.
    On March 28, 2024, the Company and Merger Sub filed the Plan of Merger with the Registrar of Companies of the Cayman Islands, which was registered by the Registrar of Companies of the Cayman Islands as of March 28, 2024, pursuant to which the Merger became effective on March 28, 2024 (the “Effective Time”). As a result of the Merger, the Company became a wholly owned subsidiary of Parent.
    The consummation of the Merger was financed through a combination of (i) rollover equity from the Rollover Shareholders, and (ii) cash contributions by the Sponsors in the amount of US$52.4 million. Due to certain logistics matters in relation to the equity rollover, two Rollover Shareholders (the “Electing Rollover Shareholders”) elected to pay to Parent an aggregate amount equal to the product of (x) the number of ADSs representing Shares such Electing Rollover Shareholders agreed to rollover pursuant to the Support Agreement, and (y) the Per ADS Merger Consideration, and will receive, through Depositary, such aggregate amount (excluding any fees, including ADS cancellation or termination fees, payable by such Electing Rollover Shareholders in accordance with the deposit agreement, dated June 18, 2020, entered into by and among the Company, the Depositary and all holders and beneficial owners of ADSs issued thereunder). As a result, the aggregate merger consideration paid by the Buyer Group and the ordinary shares of Parent that the Electing Rollover Shareholders received upon Effective Time remained the same.
    At the Effective Time, each ordinary share issued and outstanding immediately prior to the Effective Time, other than the Excluded Shares (excluding certain Excluded Shares beneficially owned by the Electing Rollover Shareholders) and Shares represented by ADSs, was cancelled and ceased to exist in exchange for the right to receive US$0.272 per ordinary share in cash, and each ADS issued and outstanding immediately prior to the Effective Time (including certain rollover ADSs owned by the Electing Rollover Shareholders), together with the Shares represented by such ADSs, was cancelled and ceased to exist in exchange for the right to receive US$4.08 per ADS in cash. The aggregate amount of merger consideration paid for the rollover ADSs owned by the Electing Rollover Shareholders was borne by such Electing Rollover Shareholders and not Sponsors. At the Effective Time, the Excluded Shares (other than certain Excluded Shares beneficially owned by the Electing Rollover Shareholders in the form of ADSs), issued and outstanding immediately prior to the Effective Time, were cancelled and ceased to exist without payment of any consideration or distribution therefor.
    As a result of the Merger, the ADS program for the ADSs will terminate and the ADSs will no longer be listed on any securities exchange or quotation system, including Nasdaq Global Market (“Nasdaq”), and the Company will cease to be a publicly traded company. The Nasdaq has filed an application on Form 25 with the SEC to remove the ADSs from listing on Nasdaq and withdraw registration of the Company’s registered securities under the  Act. The deregistration will become effective 90 days after the filing of Form 25 or such shorter period as may be determined by the SEC. The Company intends to suspend its reporting obligations under the Act by filing a certification and notice on Form 15 with the SEC. The Company’s reporting obligations under the Act will be suspended immediately as of the filing date of the Form 15 and will cease once the deregistration becomes effective. Accordingly, this Amendment No. 1 constitutes an exit filing for the Reporting Persons.

    Item 5. Interest in Securities of the Issuer.
    Item 5 of the Schedule 13D is hereby amended and restated as follows:
    (a) As of the date of this Amendment No. 1, the Reporting Persons do not beneficially own any ordinary shares.
    (b) As of the date of this Amendment No. 1, the Reporting Persons do not have any voting power or dispositive power over any ordinary shares.
    (c) Except as set forth in Item 4 of this Amendment No. 1, none of the Reporting Persons has effected any transactions in the ordinary shares during the past 60 days.
    (d) Not applicable.




    CUSIP No. 37186H209
    13D
    Page 4 of 6 Pages

    (e) At the Effective Time, each of the Reporting Persons ceased to be the beneficial owner of more than 5% of ordinary shares.





    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: March 29, 2024
       
         
    Sizhen Wang
     
    /s/ Sizhen Wang
       
    Sizhen Wang
         
         
    FHP Holdings Limited
    By:  
    /s/ Sizhen Wang
       
    Name:  
    Sizhen Wang
    Title:
    Director




    SCHEDULE A

    EXECUTIVE OFFICER AND DIRECTOR

    FHP Holdings Limited
     

    The business address of the following individual is 1-2/F, Building 11, Zone 1, No.8 Life Science Parkway, Changping District, Beijing, 102206, People’s Republic of China. Mr. Sizhen Wang is the co-founder, chairman of the board of directors and chief executive officer of the Company.
     
    Directors:
     
    Name
     
    Country of Citizenship
    Sizhen Wang
     
    The People’s Republic of China
     
     
     
    Executive Officers:

    None


    Get the next $GTH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GTH
    SEC Filings

    View All

    SEC Form 15-12G filed by Genetron Holdings Limited

    15-12G - Genetron Holdings Ltd (0001782594) (Filer)

    4/8/24 6:04:10 AM ET
    $GTH
    Medical Specialities
    Health Care

    SEC Form S-8 POS filed by Genetron Holdings Limited

    S-8 POS - Genetron Holdings Ltd (0001782594) (Filer)

    3/29/24 6:02:34 AM ET
    $GTH
    Medical Specialities
    Health Care

    SEC Form 25-NSE filed by Genetron Holdings Limited

    25-NSE - Genetron Holdings Ltd (0001782594) (Subject)

    3/28/24 4:24:30 PM ET
    $GTH
    Medical Specialities
    Health Care

    $GTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genetron Health Announces Completion of Going Private Transaction

    BEIJING, March 28, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today the completion of its merger (the "Merger") with Genetron New Co Limited ("Merger Sub"), pursuant to the previously announced agreement and plan of merger, dated as of October 11, 2023 (the "Merger Agreement"), among the Company, New Genetron Holding Limited ("Parent") and Merger Sub. As a result of the Merger, the Company has become a wholly owned subsidiary of Parent and wil

    3/28/24 1:30:11 PM ET
    $GTH
    Medical Specialities
    Health Care

    Genetron Health Announces Shareholders' Approval of Merger Agreement

    BEIJING, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that at an extraordinary general meeting of shareholders (the "EGM") held today, the Company's shareholders voted in favor of, among other things, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of October 11, 2023 (the "Merger Agreement"), among the Company, New Genetron Holding Limited ("Parent") and Genetron New Co Limite

    2/21/24 6:00:00 AM ET
    $GTH
    Medical Specialities
    Health Care

    Genetron Health to Hold Extraordinary General Meeting of Shareholders

    BEIJING, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has called an extraordinary general meeting of shareholders (the "EGM"), to be held at on February 21, 2024 at 9:00 a.m. (Beijing time) at 1/F, Building 11, Zone 1, No. 8 Life Science Parkway, Changping District, Beijing, People's Republic of China, to consider and vote on, among other matters, the proposal to authorize and approve the previously announced agreement and

    1/17/24 6:05:00 AM ET
    $GTH
    Medical Specialities
    Health Care

    $GTH
    Leadership Updates

    Live Leadership Updates

    View All

    Genetron Health Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee

    BEIJING, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that the special committee (the "Special Committee") of the Company's Board of Directors (the "Board") has retained Kroll, LLC (operating through its Duff & Phelps Opinions Practice) as its independent financial advisor and Davis Polk & Wardwell LLP as its independent legal counsel. The Special Committee was formed to evaluate and consider the previously announced preliminary

    9/2/22 7:00:00 AM ET
    $GTH
    Medical Specialities
    Health Care

    TellBio Unveils Next-Generation Liquid Biopsy Platform Focused on Early Detection and Treatment of Cancer

    --Closes $5 million Series A financing-- --Appoints Pritesh J. Gandhi, PharmD, as Chief Executive Officer and Annie Partisano, PharmD, MS, as Senior Vice President and Head of Operations-- --Announces exclusive license of TellDx platform to Genetron Holdings Limited for China-- --Secures Deployment of TellDx at ARUP Laboratories, Inc-- BEVERLY, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- TellBio, Inc., a development stage biotechnology company focused on revolutionizing the detection and treatment of cancer through its unique and proprietary circulating tumor cell (CTC) technology, TellDx, and complementary therapeutics platform, TellRx, today announced the closing of a $5 million Series A

    5/10/21 7:00:00 AM ET
    $GTH
    Medical Specialities
    Health Care

    $GTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)

    SC 13D/A - Genetron Holdings Ltd (0001782594) (Subject)

    4/2/24 5:44:00 PM ET
    $GTH
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)

    SC 13D/A - Genetron Holdings Ltd (0001782594) (Subject)

    4/1/24 4:15:35 PM ET
    $GTH
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)

    SC 13D/A - Genetron Holdings Ltd (0001782594) (Subject)

    3/29/24 8:04:05 AM ET
    $GTH
    Medical Specialities
    Health Care

    $GTH
    Financials

    Live finance-specific insights

    View All

    Genetron Health Reports Unaudited First Quarter 2022 Financial Results

    BEIJING, June 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its unaudited financial results for the first quarter ended March 31, 2022. First Quarter and Recent Highlights Recorded total revenue of RMB 110.3 million (US $17.4 million) in the first quarter of 2022, representing 19.8% increase over the same period in 2021. LDT revenue was RMB 81.5 million (US $12.9 million), representing 13.5% increase over the same period in 2021.IVD re

    6/2/22 7:19:58 AM ET
    $GTH
    Medical Specialities
    Health Care

    Genetron Health to Announce First Quarter 2022 Unaudited Financial Results and Host Investor Call on June 2, 2022

    BEIJING, May 23, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the first quarter ended March 31, 2022 on June 2, 2022 before the US market open. Management will host a conference call for investors at 8:30 a.m. ET (8:30 p.m. Beijing time) on Thursday, June 2, 2022. The conference call can be accessed by dialing the following numbers: United States:+1-833-239-5565China Domestic:400-820-528

    5/23/22 4:05:00 PM ET
    $GTH
    Medical Specialities
    Health Care

    Genetron Health Announces Unaudited Fourth Quarter and Full Year 2021 Financial Results

    BEIJING, March 29, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced its unaudited preliminary financial results for the fourth quarter and full year ended December 31, 2021. 2021 and Recent Business Highlights Therapy Selection: As of December 31, 2021, the Company had 58 hospital partners, of which 30 were IVD hospital partners. Genetron Health is continuing to enhance its in-hospital sales effort.

    3/29/22 7:26:05 AM ET
    $GTH
    Medical Specialities
    Health Care